96 0.05 IP6 + Inositol Group 78.33 ± 21.60 Functional scale (FS) Answering questions about certain functions in everyday life, the RO4929097 average score was 87.9 in C188-9 patients who have taken IP6 + Inositol, while in patients who have taken placebo, the average score on the functional scale was 56.3 (p = 0.0003) (Table 2). The difference between the average scores between the two groups was statistically significant, showing that that the functional status of patients who were taking IP6 + Inositol in addition to chemotherapy was significantly better preserved, in relation to the control group. Table 2 Patients Personal Assessment
of their Functional Status Functional Status Patients Mean ± SD p value Placebo Group 56.29 ± 15.32 0.0003 IP6 + Inositol Group 87.94 ± 6.94 Simptomatic scale (SS) Among the patients who where taking IP6 + Inositol, the average score of answers on questions
about the symptomatic scale was 13.5, while that score in the control group was 33.8. The diference of the average scores between two groups is statistically significant (p = 0.04) (Table 3). Table 3 Patients Personal Assessment of Side Effects of Therapy (Symptomatic Scale) Clinical Symptoms of Side Effects of Therapy Patients Mean ± SD p value Placebo Group 33.81 ± 18.12 0.04 IP6 + Inositol Group 13.51 ± 9.98 Results of laboratory tests Before treatment, the average number of leukocytes in the group of patients who were taking IP6 + Inositol was 6.66 (5.1-7.7) × 109/L, and after the treatment was 6.92 (3.8-9.1) × 109/L, an average increase of 0.26. In the group of patients who were on placebo, the average number of leukocytes before treatment was 7.53 (6.2-10.4) × 109/L and Belinostat datasheet 4.36 (1,18-6.5) × 109/L after the treatment; an average decrease of 3.17. In the control group of pheromone patients there was a statistically significant fall in the number of leukocytes after treatment compared to the number of leukocytes before treatment (p = 0.01), while in the experimental group on IP6 + Inositol, not only that the number of leukocytes did not change
(p = 0.75), but it was even slightly increased (Table 4). Table 4 Change in Complete Blood Cell Count Values Blood Cells Placebo Group (Mean ± SD) IP6 + Inositol Group (Mean ± SD) White Blood Cell Count (×109/L) Before Treatment 7.53 ± 1.50 6.66 ± 0.96 After Treatment 4.36 ± 1.80 6.92 ± 2.12 p value 0.01 0.75 Platelet Count (×109/L) Before Treatment 272.71 ± 114.86 229.57 ± 31.81 After Treatment 205.00 ± 90.56 231.86 ± 47.33 p value 0.05 0.92 Red Blood Cell Count (×1012/L) Before Treatment 4.45 ± 0.71 4.23 ± 0.71 After Treatment 4.05 ± 0.52 4.48 ± 0.23 p value 0.23 0.39 Hemoglobin (g/L) Before Treatment 122.00 ± 17.28 127.00 ± 19.94 After Treatment 119.43 ± 10.78 135.86 ± 10.16 p value 0.68 0.36 The average number of platelets before treatment was 229.57 (204-296) × 109/L in a group of patients who were taking IP6 + Inositol, while after the treatment it was 231.86 (182-322)× 109/L, representing an increase of 2.